{
  "scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Single-Cell Spatial Transcriptome Analysis in a Randomised Controlled Trial of Anti-PD-L1 Therapy Combined with Chemoradiotherapy for NSCLC"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "Participants were randomised to receive either preoperative CRT or preoperative ICI-CRT."
      },
      "Participants": {
        "score": 2,
        "evidence": "The study was conducted at the National Comprehensive Cancer Study Board (NCCHE) with eight patients at UICC 8th Stage IIIA."
      },
      "Intervention": {
        "score": 2,
        "evidence": "Participants were randomised to receive either preoperative CRT or preoperative ICI-CRT."
      },
      "Objective": {
        "score": 1,
        "evidence": "This randomised controlled trial investigates the effects of anti-PD-L1 therapy combined with chemoradiotherapy (CRT) on the tumour microenvironment in unresectable non-small cell lung cancer (NSCLC)."
      },
      "Method_Outcome": {
        "score": 1,
        "evidence": "The primary outcome was the alteration in immune environment, measured at the single-cell level."
      },
      "Randomisation_Allocation": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Blinding": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "The study was conducted at the National Comprehensive Cancer Study Board (NCCHE) with eight patients at UICC 8th Stage IIIA."
      },
      "Number_Analysed": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Result_Outcome": {
        "score": 2,
        "evidence": "Posttreatment, there was a significant increase in CXCL9+ cells and CXCL13+ T cells around tumour cells."
      },
      "Harms": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "The trial was registered under Protocol Number 2022-407."
      },
      "Funding": {
        "score": 1,
        "evidence": "The study was funded by the National Comprehensive Cancer Study Board."
      }
    },
    "total_score": 13,
    "max_score": 25
  },
  "model": "gpt-4o"
}